bluuebunny/crossref_metadata_2025 huggingface dataset:
911-P: Effect of Dapagliflozin on Blood and Breath Ketones during Supervised Insulin Withdrawal in Adults with Type 1 Diabetes
Authors: PETERSEN MAX C. , JONES KAI E. , BOHNERT KATHRYN L. , MARKOV ALEXANDER M. , SALAM MAAMOUN , KRUTILOVA PETRA , MCKEE ALEXIS M. , ADAMSON SAMANTHA E. , MCGILL JANET B.
Published: June 2024

Introduction: SGLT2 inhibitors increase DKA risk, limiting their use in T1D. To understand the effect of SGLT2i on ketone production, we measured glucose, beta-hydroxybutyrate (BOHB) and breath acetone (BrACE) with and without dapagliflozin during supervised insulin withdrawal in adults with T1D.

Methods: 20 adults with T1D underwent on-site supervised insulin withdrawal twice in a randomized crossover design: during usual care and after treatment with dapagliflozin (10 mg daily for 2 weeks plus the test day). After insulin withdrawal, capillary blood glucose, BOHB, and BrACE measurements were obtained at least hourly until stopping rules were met (glucose >400 mg/dL, BOHB >3 mmol/L, >8 hours elapsed, or participant request).

Results: Mean (± SD) age was 48 ± 18 years, with baseline HbA1c 7.0 ± 0.9%. The maximal BOHB and BrACE values achieved during supervised insulin withdrawal were both greater with dapagliflozin than usual care (BOHB: 2.4 ± 1.2 vs. 1.6 ± 1.0 mmol/L, P <0.001; BrACE: 13.7 ± 7.5 vs. 8.7 ± 5.7, P = 0.004). Adjusted for time from insulin withdrawal, dapagliflozin treatment was associated with significantly greater BOHB and BrACE concentration (both P <0.001 by ANCOVA). The proportions of participants reaching BOHB >1.5 mmol/L and >2.5 mmol/L during supervised insulin withdrawal were greater in the dapagliflozin arm (74% vs. 37% with BOHB >1.5 mmol/L; 53% vs. 16% with BOHB >2.5 mmol/L; both P <0.05 by McNemar’s test). Blood glucose reached a lower maximum (218 ± 53 vs. 302 ± 58 mg/dL, P <0.001) in the dapagliflozin arm and did not significantly change during insulin withdrawal in the dapagliflozin arm (P for linear trend = 0.91).

Conclusion: In adults with T1D undergoing up to 8 hours of supervised insulin withdrawal after dapagliflozin treatment, blood and breath ketone concentrations were significantly greater compared to usual care and in the absence of significant hyperglycemia.

Disclosure

M.C. Petersen: None. K.E. Jones: None. K.L. Bohnert: None. A.M. Markov: None. M. Salam: None. P. Krutilova: None. A.M. McKee: Advisory Panel; Medtronic, Novo Nordisk. Employee; Novo Nordisk. S.E. Adamson: None. J.B. McGill: Advisory Panel; Bayer Inc., Boehringer-Ingelheim, ClearNote Health, Lilly Diabetes, MannKind Corporation, Novo Nordisk. Research Support; Novo Nordisk.

Funding

JDRF (2-SRA-2022-1190-M-B)
914-P: Association of Sodium–Glucose Cotransporter 2 Inhibitors with Risk of Diabetic Ketoacidosis among Hospitalized Patients—A Multicentre Cohort Study
Authors: SARMA SHOHINEE , HODZIC-SANTOR BENAZIR , COLACCI MICHAEL , VERMA AMOL A. , RAZAK FAHAD , RAISSI AFSANEH , LASSEN MATS C.H. , FRALICK MICHAEL
Published: June 2024

Importance: Sodium glucose co-transporter-2 (SGLT-2) inhibitors are being used among hospitalized patients, but there is no real-world empiric data on the risk of diabetic ketoacidosis (DKA) in-hospital. Objective: To assess the risk of DKA with SGLT-2 inhibitor use during hospital stay.

Design, Setting, Participants: We conducted a multi-centre cohort study of hospitalized patients in 19 hospitals in Canada between January 1, 2015 and December 31, 2021. We included patients over age 18 years with type 2 diabetes mellitus who received an SGLT-2 inhibitor or a dipeptidyl peptidase-4 (DPP-4) inhibitor in hospital. Exposure: SGLT-2 inhibitor

Comparator: DPP4-inhibitor

Main Outcomes and Measures: The primary outcome was the risk of DKA defined using American Diabetes Association (ADA) DKA criteria (pH <7.30, bicarbonate less than 18 mmol/l and positive ketones). Patients were followed from the date of admission to hospital to date of discharge or occurrence of DKA.

Results: We identified 11,098 patients who received an SGLT-2 inhibitor and 67,429 who received a DPP-4 inhibitor. The average age was 67.7 years (SD: 18.3 years), and 47.7% were women. In the matched population, the risk of DKA was 0.06% (N=6 events) over 5.2 hospital days with DPP-4 inhibitors and 0.19% (N=20 events) over 5.4 hospital days with SGLT-2 inhibitors. The relative risk was 3.33 (95% CI 1.33 - 8.30) for SGLT-2 inhibitors compared to DPP-4 inhibitors.

Conclusion and Relevance: Among hospitalized patients, the risk of DKA with use of SGLT-2 inhibitors was three-fold higher compared to DPP-4 inhibitors, but the absolute risk of DKA was low.

Disclosure

S. Sarma: None. B. Hodzic-Santor: None. M. Colacci: None. A.A. Verma: None. F. Razak: None. A. Raissi: None. M.C.H. Lassen: None. M. Fralick: Consultant; singal1, proofdx.
918-P: Effect of Remogliflozin in Improving NYHA Class Compared with Empagliflozin in Type 2 Diabetes Patients with Heart Failure (Remit HF)
Authors: BARKATE HANMANT V. , PANCHAL YASH , BHUSHAN SUMIT , CHOUDHARI SANJAY Y. , PETARE ANUP U.
Published: June 2024

Background: In patient of T2DM and HF, reduced ejection fraction (HFrEF) constitutes the majority of HF cases, posing significant risk of mortality. NYHA classification, recommended in global HF guidelines, independently predicts mortality. SGLT2i have shown to reduce the incidence of hospitalization for HF. Hence, this study was planned to evaluate the effectiveness of Remogliflozin in improving the NYHA class in patients of T2DM with HF.

Methods: In this prospective, multicentre study, 250 patients of T2DM with HFrEF having NYHA Class I to III, were enrolled. 125 patients were allocated each to Remogliflozin (R) and Empagliflozin (E) group.

Results: Baseline distribution of patients in NYHA class was comparable in both groups. At baseline, 4%, 78.4%, and 17.6% of the patients in R-group were in NYHA class I, II, and III respectively, which improved to 50.91% in class I, 42.73% in class II, and 6.36% in class III at week 24 (Figure 1). Similarly, in E-group, about 4.8%, 64.8%, and 30.4% of the patients were in NYHA class I, II, and III and improved to 48.5% in class I, 40.9% in class II, and 10.5% in class III at week 24. Percentage improvement in NYHA class by ≥1 grade was seen in both R and E-group (80% vs 76%) at 24 weeks. The positive improvement in NYHA class indicates that the treatment provided improved patient’s function class and QoL. Both groups showed significant improvement in echo parameters (LVEF, LVdd) with no new safety concerns reported.

Conclusion: The improvement in NYHA class was comparable between Remogliflozin and Empagliflozin in patients of T2DM patients and HF (HFrEF). These clinical benefits were irrespective of baseline NYHA class and was associated with early and sustained improvement in NYHA class over study duration.

Disclosure

H.V. Barkate: Employee; Glenmark Pharmaceuticals. Y. Panchal: None. S. Bhushan: None. S.Y. Choudhari: Employee; Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd. A.U. Petare: Employee; Glenmark Pharmaceuticals.
944-P: Impact of Salt Reduction on Nocturia in Patients with Type 2 Diabetes—The TOP-STAR Study
Authors: SAIJO YUTO , OKADA HIROSHI , NAKAJIMA HANAKO , KOGURE AKINORI , OSAKA TAKAFUMI , TSUTSUMI TAKESHI , TANAKA TORU , HASEGAWA GOJI , MOGAMI SHINICHI , MITSUHASHI KAZUTERU , KITAGAWA NORIYUKI , HASHIMOTO YOSHITAKA , YANO MIHO , TANAKA MUHEI , KITAMURA AKANE , ISHII MICHIYO , NAKAMURA NAOTO , KISHI AKIO , USHIGOME EMI , HAMAGUCHI MASAHIDE , FUKUI MICHIAKI
Published: June 2024

Title: Impact of Salt Reduction on Nocturia in Type 2 Diabetes Patients: The TOP-STAR Study

Introduction & Objective: This study addresses the prevalence of nocturia in type 2 diabetes patients, a condition often exacerbated by SGLT2 inhibitors. Recognizing the potential role of dietary salt in nocturnal urination, the study aims to evaluate the effect of salt reduction instruction combined with tofogliflozin therapy. We hypothesize that dietary salt restriction, alongside SGLT2 inhibitor use, may alleviate nocturia in this population.

Methods: The TOP-STAR study is a multi-center, open-label, randomized trial involving 80 patients with type 2 diabetes experiencing nocturia. Participants were randomly assigned to two groups: one receiving standard care with tofogliflozin therapy, and the other receiving additional salt reduction instructions. The primary outcome measured was the change in frequency of nocturnal urination over 12 weeks. Secondary outcomes included nocturnal urine volume and overall quality of life assessments.

Results: as follows; the average nocturia frequencies at baseline and 12 weeks were 1.3 [0.9-2.1] and 1.1 [0.5-1.9] vs and 1.5 [0.7-2.1] vs 1.4 [1.0-1.7] times per day respectively. The changes in nocturnal urine volume were -39.2 [-146.7-81.6] vs -71.7 [-218.3-78.4] mL (p=0.29). The changes in diurnal urine volume were 337.1 [41.6-513.4] vs 289.2 [7.2-490.8] mL (p=0.77).

Conclusion: Our findings indicate no significant superiority of salt restriction in reducing the frequency of nocturnal urination. However, tofogliflozin therapy was not associated with an increase in nocturia frequency and may contribute to a decrease in nocturnal urine volume. Notably, a subset of patients adhering strictly to salt reduction showed a trend towards reduced nocturia, suggesting potential individual benefits.

Disclosure

Y. Saijo: None. H. Okada: None. H. Nakajima: None. A. Kogure: None. T. Osaka: None. T. Tsutsumi: None. T. Tanaka: None. G. Hasegawa: None. S. Mogami: None. K. Mitsuhashi: None. N. Kitagawa: None. Y. Hashimoto: None. M. Yano: None. M. Tanaka: None. A. Kitamura: None. M. Ishii: None. N. Nakamura: None. A. Kishi: None. E. Ushigome: Speaker's Bureau; Boehringer-Ingelheim, Daiichi Sankyo, Novo Nordisk Foundation, Taisho Pharmaceutical Holdings Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. Research Support; Taiyo Kagaku Co., Ltd., Yoshinoya holdings. M. Hamaguchi: None. M. Fukui: None.
947-P: Retrospective CGM-Driven Missed-Meal Bolus Detection Tool
Authors: BENEDETTI ANDREA , MIKHNO ARTHUR , ROY ANIRBAN , SHIN JOHN
Published: June 2024

Introduction: Remembering to deliver insulin before meals represents a significant burden for people with diabetes (PWD) and often results in late or entirely missed meal boluses.1,2 A new Medtronic CGM-driven retrospective meal-detection (MD) tool was developed and used to retrospectively identify missed meal events in a MiniMed™ 780G system (MM780G) pivotal trial that included an unannounced meal evaluation.

Methods: The CGM-driven missed meal detection tool integrates a Machine Learning model trained on CGM and insulin data for meal identification, combined with a local adjustment of the meal start time. Study participants (N=155, aged 7-75 years with T1D) using the MM780G were directed to abstain from announcing one meal each day for a duration of 5 days, while recording both the time and carb amount of these ‘test’ meals in a diary. The new MD algorithm was evaluated on 600 unannounced meals and its performance was characterized by recall rate and delay of missed meals.

Results: The model was able to detect 91% (recall) of test meals with a mean delay of 12.9 (38.4) minutes.

Conclusion: The Medtronic missed meal-detection algorithm can accurately mark missed meal events and support in-depth analysis of glycemic outcomes. Providing healthcare professionals with a more comprehensive understanding of mealtime behavior will enable more informed therapy decisions and the possibility of improved glycemic outcomes.

Disclosure

A. Benedetti: None. A. Mikhno: Employee; Medtronic. A. Roy: Employee; Metronics. J. Shin: None.
955-P: Effective Use of U-200 Insulin in OmniPod 5, Medtronic 780G, and Tandem X2 Systems
Authors: AKCAN TUGCE , NEEDLEMAN LEOR , BASINA MARINA
Published: June 2024

Objectives: Commercially available insulin pumps are approved for U-100 insulin. Patients with high insulin dose requirements need to change infusion sets every 1-2 days, creating inconvenience and increasing costs. We evaluated the safety and feasibility of using U-200 insulin in hybrid closed-loop systems.

Methods: We reviewed clinical data and insulin pump uploads from three patients using U-200 insulin in their pumps, each diagnosed with a different type of diabetes: Type 1, Type 2, and post-pancreatitis. Each patient used a different hybrid closed-loop system in automated mode: OmniPod 5, Medtronic 780G, and Tandem X2. Insulin doses were reduced by 50% when programming the pump settings for U-200, with minor individual variations.

Results: Using U-200 insulin extended the infusion set wear from 1-2 days to 3 days. For the patient using the Medtronic 780G, Time in Range (TIR) improved by 57% in the month after transitioning to U-200 insulin. The Glucose Management Indicator (GMI) decreased from 9.6% to 7.4%, with SmartGuard mode active 73% of the time. Similarly, for the patient using the Tandem X2, TIR increased by 33% over a month, and GMI improved from 8.7% to 7.5%, with the patient in Control IQ mode 94% of the time. The patient using OmniPod 5 showed a 6% improvement in TIR and was in automated mode 100% of the time, with GMI improving from 6.7% to 6.5%. There was no increase in time spent in hypoglycemia with U-200 insulin. All three patients reported enhanced quality of life and increased satisfaction with their pump therapy.

Conclusion: The use of U-200 insulin in hybrid closed-loop system algorithms was safe and effective, offering a viable option for automated insulin delivery systems (AIDS) in patients with high insulin needs. This approach could also broaden the application of AIDS to different types of diabetes, as evidenced by our patients. This is the first reported case series to date. Further studies are necessary to establish standardized recommendations for using concentrated insulins in AIDS.

Disclosure

T. Akcan: None. L. Needleman: None. M. Basina: None.
959-P: Multiple Daily Injection (MDI) to Automated Insulin Delivery (AID) vs. Non-AID Insulin Pump for Newly Diagnosed People with Type 1 Diabetes Offers Improvement in Glycemic Control
Authors: ROMPICHERLA SAKETH , MILLER KELLEE , CHAO LILY C. , AKTURK HALIS K. , ALONSO GUY T. , DAVIS GEORGIA M. , DESALVO DANIEL , WEINSTOCK RUTH S. , HSIEH SUSAN , KAMBOJ MANMOHAN K. , RAPAPORT ROBERT , EBEKOZIEN OSAGIE , COLLABORATIVE T1DX-QI
Published: June 2024

Automated insulin delivery relates to lower HbA1c values in people with type 1 diabetes (PwT1D) participating in clinical trials, but real-world evidence is lacking.

This observational crossover study used medical record data from PwT1D newly diagnosed between 2019-2023 from 32 centers in the T1D Exchange Quality Improvement Collaborative. We used real-world Electronic medical record (EMR) data to examine HbA1c levels among people with type 1 diabetes (PwT1D) classified as MDI users after T1D diagnosis and changed to AID during follow-up, versus people who changed to non-AID pump therapy. We compared HbA1c levels when initially using MDI to HbA1c levels after starting insulin pump therapy with and without AID.

There were 1,578 PwT1D who changed from MDI to AID after median (IQR) duration of 2.1 (2.3) years and 2,825 who changed to non-AID pump therapy after 0.8 (1.2) years. Among PwT1D who changed to AID, median (IQR) HbA1c decreased from 7.7 (1.7) to 7.4 (1.7) and HbA1c decreased from 8.0 (1.9) to 7.9 (1.9) among those changing to non-AID pump therapy. Odd Ratio (95% CI) of having an HbA1c < 7.0% was 1.60 (1.34, 1.92) when changing to AID compared to non-AID pump therapy after adjusting for confounders.

We saw a greater decline in HbA1c levels and severe hypoglycemic episodes observed in AID users vs those using non-AID pump therapy.

Disclosure

S. Rompicherla: None. K. Miller: Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. L.C. Chao: None. H.K. Akturk: Consultant; Medtronic. Research Support; Medtronic. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. G.T. Alonso: Advisory Panel; MannKind Corporation. G.M. Davis: Research Support; Insulet Corporation. Consultant; Medscape. D. DeSalvo: Advisory Panel; Insulet Corporation. Consultant; Dexcom, Inc. R.S. Weinstock: Research Support; Eli Lilly and Company, Tandem Diabetes Care, Inc., Diasome, Amgen Inc., MannKind Corporation, Insulet Corporation, Novo Nordisk. Other Relationship; Dexcom, Inc. S. Hsieh: None. M.K. Kamboj: None. R. Rapaport: None. O. Ebekozien: Advisory Panel; Sanofi, Medtronic. Research Support; Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; Medtronic, Lilly Diabetes, Abbott, Dexcom, Inc.

Funding

Helmsley Charitable Trust
96-OR: Pancreatic Adverse Events and Mortality in Patients with Immune Checkpoint Inhibitor–Associated Diabetes Mellitus—A 10-Year Follow-up Study
Authors: RAZA RIZVI SHAFAQ , JEET KAUR RAVINDER , REID COREY , DESJARDINS DONNA , KUDVA YOGISH C.
Published: June 2024

Objectives/Introduction: Immune mediated pancreatic injury is a well-known side effect of immune checkpoint inhibitors (ICI) but there are lack of data regarding Pancreatic Adverse Events (PAEs) in patients with ICI related diabetes mellitus (ICI-DM).

Methods: We collected data from 31 subjects who were evaluated for ICI-DM at Mayo Clinic, Rochester from 2014 to 2023. PAEs were defined as new onset pancreatic disease (NOPD) or worsening of preexisting pancreatic disease (PPD) including acute or chronic pancreatitis, pancreatic cyst and pancreatic atrophy ± fatty replacement after ICI.

Results: We divided subjects into 2 cohorts: those with Cohort 1 with PAEs (n=14) and Cohort 2 without PAE (n=17) with more details in Table. There were no significant differences in age, BMI, PPD, pembrolizumab use, steroid use, HbA1c at DM onset or worsening of DM, follow-up time and mortality between the 2 cohorts. Cohort 1 experienced 16 PAEs; 9 subjects without PPD developed 11 new events (NOPD) and 5 subjects with PPD experienced PAEs. None of the other 4 subjects with PPD in cohort 2 experienced PAEs

Conclusion: In a single center, reasonable size cohort of ICI DM, pancreatic disease was induced or aggravated without increase in mortality. Further studies of this population are needed.

Disclosure

S. Rizvi: None. R. Kaur: None. C. Reid: None. D. Desjardins: None. Y.C. Kudva: Research Support; Dexcom, Inc. Other Relationship; Tandem Diabetes Care, Inc., Medtronic.
960-P: Perceived Consequences of AID Systems for the Care of People with Diabetes in Switzerland, Austria, and Germany
Authors: HERMANNS NORBERT , EHRMANN DOMINIC , ROOS TIMM , HEINEMANN LUTZ , KULZER BERNHARD
Published: June 2024

AID systems are becoming increasingly popular among people with type 1 diabetes (pwt1d). As part of the Diabetes Report, we asked Pwt1d (n=1920) and parents of children with type 1 diabetes (n=210) in three countries (Germany, Austria and Switzerland) about the expected consequences of the increased use of AID systems. On a 5-point Likert scale (1=strongly disagree - 5=strongly agree), respondents were rather indifferent regarding the need for training programs specifically for AID systems. In contrast, the expectation of increased autonomy among AID users was very positive. On the other hand, respondents were rather negative about the statements that many users do not get along with AID systems, that there is less contact with the diabetes team as a result, that diabetes therapy becomes riskier as a result of AID systems, or that treatment in a diabetes clinic becomes more superfluous as a result. Generally, parents of children with diabetes were even more positive about AID systems than pwt1d (all p<0.05), while there were no significant differences between the 3 countries (all p>0.05). Pwt1d or their parents expect greater autonomy through the use of AIDs, whereas negative expectations regarding th AID impact on future diabetes care were rather low.

Disclosure

N. Hermanns: Speaker's Bureau; Berlin-Chemie AG, Sanofi-Aventis Deutschland GmbH. Research Support; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Roche Diabetes Care. Research Support; Roche Diabetes Care. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Abbott Diagnostics, Ypsomed AG. D. Ehrmann: Advisory Panel; Dexcom, Inc. Speaker's Bureau; Dexcom, Inc., Sanofi-Aventis Deutschland GmbH. Advisory Panel; Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care, Berlin-Chemie AG. T. Roos: None. L. Heinemann: Stock/Shareholder; Science Consulting in Diabetes GmbH, Profil Institut für Stoffwechselforschung GmbH. Advisory Panel; embecta. Board Member; Lifecare A/S. Stock/Shareholder; diateam GmbH. B. Kulzer: Advisory Panel; Abbott Diagnostics, Berlin-Chemie AG, Dexcom, Inc., Sanofi, embecta, Novo Nordisk, Roche Diabetes Care. Speaker's Bureau; Bayer Inc., Insulet Corporation, Lilly Diabetes.
966-P: Diabetes Technology Outcomes in the Vulnerable Early Childhood Population at a Large Diabetes Clinic
Authors: TABATABAI IDEEN , ALONSO GUY T. , FORLENZA GREGORY P.
Published: June 2024

Intro: As more diabetes technology is approved for children down to age 2 and off-label use expands, clinical outcomes data for young children on these devices are sparse. We evaluated real-world device usage and the glycemic results in this vulnerable population.

Methods: Retrospective data were collected on all patients with T1D under age 7 years at a large, tertiary care center diabetes clinic (n=230; age 1.1 to 6.8 years). We performed two-sample t-tests by device use (AID vs MDI) for glycemic outcomes (HbA1c, Time in Range 70-180 mg/dL (TIR), Time Below range (TBR) < 70, Time Above Range (TAR) >180 and >250 mg/dL) and insulin dosing parameters. Patients seen in the last 12 months were included.

Results: Use of AID was associated with significantly greater TIR, lower HbA1c, less TBR < 70 mg/dL, and less glucose variability (all p<0.05) (Table 1). Notably, TAR >250 mg/dL was significantly reduced by 9%. AID users have significantly increased total daily insulin use (0.75u/kg/day on AID vs 0.62u/kg units on MDI, p=0.005), but without significant difference in basal to bolus ratios (mean basal 42 to 44% of TDD, p = ns).

Conclusion: In young children with type 1 diabetes at a large clinic, the majority of patients use CGM and AID, but nearly 1/3 do not use AID. Among those using AID, glycemic improvement outcomes were similar to clinical trial results, particularly in minimizing incidence of hyperglycemia and hypoglycemia.

Disclosure

I. Tabatabai: None. G.T. Alonso: Advisory Panel; MannKind Corporation. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc.
973-P: New Paradigms for Wearability with the Tandem Mobi System
Authors: HABIF STEPHANIE , MANNING MICHELLE L. , LEAS SCOTT , MORGAN LEXI , MESSER LAUREL H.
Published: June 2024

Background: Lack of wearability options is a top cited barrier to insulin pump therapy. A new tubed insulin pump, Tandem Mobi, has a very small footprint (2 x 1.5 x .5 inches), and optional 5-inch tubing and adhesive sleeve for on-body wear, in addition to traditional wear options. Here we qualitatively assess feedback from early users, specifically to understand new options for wearing the system.

Methods: Adults (18+ years) with type 1 diabetes participated in an early product launch October-December 2023 (n=145), and wore the Tandem Mobi for >6 weeks (prior therapy = 83% Tandem t:slim X2, 12% other pumps, 5% multiple daily injections). Daily surveys were sent for open-ended user experience feedback. A total of 309 verbatim comments on the topic of wearability were received and analyzed.

Results: 102 adults using Tandem Mobi responded to surveys. Fifty-seven participants commented on using the adhesive sleeve with 5-inch tubing for on-body wear (figure). Other wear options mentioned included using pump case attached to clothing, or tucking into a pocket or bra. 15% of respondents mentioned the Tandem Mobi wearability allowed them to “forget they are wearing a pump.”

Conclusions: The Tandem Mobi’s on-body wear combined with the ability to disconnect presents a new paradigm for pump wearability. Users cite the convenience of a patch pump with the utility of a tubed pump, potentially reducing barriers to insulin pump therapy by increasing optionality.

Disclosure

S. Habif: Employee; Tandem Diabetes Care, Inc. M.L. Manning: Employee; Tandem Diabetes Care, Inc. S. Leas: Employee; Tandem Diabetes Care, Inc. L. Morgan: Employee; Tandem Diabetes Care, Inc. Stock/Shareholder; Tandem Diabetes Care, Inc. L.H. Messer: Employee; Tandem Diabetes Care, Inc.

Funding

Tandem Diabetes Care
98-OR: ß-Cell Dysfunction and Mitochondrial Loss Occur Independently of Insulitis in Type 1 Diabetes Pathogenesis
Authors: HUBER MOLLIE , WIDENER ADRIENNE , SMURLICK DYLAN , HILLER HELMUT , BEERY MARIA , VERNEY ELLEN , KUSMARTSEVA IRINA , CAMPBELL-THOMPSON MARTHA , ATKINSON MARK A. , MATHEWS CLAYTON E. , PHELPS EDWARD
Published: June 2024

Introduction: Type 1 diabetes (T1D) is characterized by a period of β cell dysfunction prior to β cell death. During this time, β cells lack a first-phase insulin response and exhibit an intolerance to glucose. However, the underlying mechanisms of this dysfunction remain unclear. Here, we use live human pancreas tissue slices (LPTS) to investigate the possible mechanisms underlying β cell dysfunction in T1D.

Methods: LPTS from organ donors without diabetes (ND, n=13), donors without T1D and positive for one (sAAb+, n=6) or multiple T1D-relavent autoantibodies (mAAb+, n=2), and individuals with short-duration T1D (T1D+, n=9) were studied. Simultaneous time-lapse Ca2+ imaging and CD3+ T-cell tracking were conducted to assess alterations in β-cell function. Additionally, fixed pancreas sections (ND, n=8; sAAb+, n=7; mAAb+, n=7; T1D+, n=6) were probed with a panel of 22 antibodies to investigate mechanisms underlying β-cell dysfunction including insulin, CD3, ATP5B (a mitochondrial ATP synthase subunit), and ATPIF1 (ATP synthase inhibitor).

Results: Islets within LPTS from ND and AAb+ donors exhibited typical Ca2+ mobilization in response to high glucose (HG) and potassium chloride (KCl) stimulations. Islets from T1D+ donors had significantly diminished Ca2+ responses to HG compared to ND donors (p<0.05, one-way ANOVA). Low glucose and KCl stimulations between ND, AAb+, and T1D+donors were similar, indicating that the dysfunction occurs in the glucose metabolism pathway. Additionally, there were no significant differences in HG responses in insulitic and non-insulitic islets from T1D+ LPTS with both being dysfunctional. Fixed tissue staining revealed a significant (p<0.0001, two-way ANOVA) decrease in mitochondria in β cells from T1D+ donors.

Conclusion: The loss of HG responses in T1D+ β cells independent of the local T cell infiltration, coupled with the decrease in mitochondria, indicates that the dysfunction likely originates in the β cell and contributes to T1D pathogenesis.

Disclosure

M. Huber: None. A. Widener: None. D. Smurlick: None. H. Hiller: None. M. Beery: None. E. Verney: None. I. Kusmartseva: None. M. Campbell-Thompson: None. M.A. Atkinson: None. C.E. Mathews: None. E. Phelps: Research Support; Immunocore, Ltd, MESO SCALE DIAGNOSTICS, LLC.

Funding

T32DK108736F31DK130607P01; AI42288 R01DK132387
980-P: Automated Insulin Delivery Clamp Technology—Proof of Concept Study
Authors: HAWKE KATE , KHAN NABEEL , FOURNIER MARC G. , ELLIOTT TOM
Published: June 2024

Introduction & Objective: Interventions designed to improve endogenous insulin production and/or reduce exogenous insulin requirements are currently assessed using C-peptide measurement & traditional clamp techniques. We propose a novel adjunctive protocol for determining insulin requirements using Automated Insulin Delivery (AID) systems, known as AID-Clamp.

Methods: With AID-Clamp (see video https://bit.ly/AIDClamp), an individual’s insulin requirement over a defined period is quantified using analysis of the AID event log. An insulin quantification script retrieves basal and bolus insulin data over the time period and provides an output of total insulin requirement.

A 55-year-old man with type 1 diabetes already using AID (open-source iAPS) opted to commence off-label tirzepatide as adjunct therapy. He reported a profound reduction in insulin requirement. We applied AID-Clamp analytics retrospectively to identical meals eaten regularly by this patient, to demonstrate its application.

Results: In the two weeks prior to tirzepatide commencement, mean insulin total daily dose was 194 units. The AID-Clamp 6-hour insulin requirement post standard-meal of 88g carbohydrate was 30.5 units. In the third week of tirzepatide use (dose 5 mg weekly), the mean insulin total daily dose was 113.4 units. The 6-hour insulin requirement post standard 88 g meal was 11.8 units.

Conclusion: AID-Clamp is a novel application for AID systems. When used in appropriate clinical or research settings, it is capable of detailed quantification of insulin requirements. The changes in insulin requirement in response to pharmacologic, lifestyle or other interventions, serve as a proxy for the effect of the intervention. AID-Clamp is non-invasive, carries no additional cost and is much quicker and less labor-intensive than traditional methods of assessing the efficacy of such interventions.

Disclosure

K. Hawke: None. N. Khan: None. M.G. Fournier: None. T. Elliott: Research Support; Biomea Fusion, Inc., Eli Lilly and Company, Novo Nordisk, GlaxoSmithKline plc, Sanofi, Janssen Pharmaceuticals, Inc. Consultant; Vertex Pharmaceuticals Incorporated, Abbott, Dexcom, Inc. Research Support; Zucara Therapeutics.
981-P: Development of a Diabetes Navigator Toolkit to Support Diabetes Technology Uptake and Sustained Use—IMPACT Toolkit
Authors: WOLF RISA M. , ALVER DEFNE , PAN BERNARD , PARIMI NEHA , KLOPOUH MILANA S. , LIU THALIA D. , LIU ABBY D. , SIDHAYE ANIKET , RIEKERT KRISTIN , MATHIOUDAKIS NESTORAS N.
Published: June 2024

Advanced diabetes technologies (ADT), including continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery systems, improve glycemic control in Type 1 diabetes. However, these technologies are underutilized, particularly in minority and underserved populations. Barriers to ADT use are well described, yet there are limited reports of solutions to improve ADT uptake. This qualitative interview study of diabetes stakeholders aimed to develop a diabetes toolkit to help improve the uptake and sustained use of ADT.

Semi-structured interviews were conducted, specifically focusing on CGM prescription, CGM education and use, pump prescription, and pump education and use. Rapid qualitative method was employed for efficient data collection and analysis. Key themes were identified and iteratively applied to refine the toolkit.

The participants included 18 providers, 10 community/commercial partners and vendors, and 23 patients/caregivers, among whom 9 used both CGM and pump, 10 used only CGM, and 4 did not use either device. Key barriers included communication lapses, insurance/cost challenges, inadequate education, technological issues, complex processes, and limited resource accessibility. For communication gaps and clinic portal connections, appointing a central liaison such as a diabetes navigator was proposed. Solutions for insurance/cost challenges involved providing transparent cost information. Education enhancements emphasized hands-on training, and providing clear device instructions. In general stakeholders supported adopting the diabetes toolkit for improved technology uptake and use.

A diabetes toolkit could be utilized by a diabetes navigator or another diabetes care team member to help improve the uptake and sustained use of diabetes technologies despite the complex processes involved.

Disclosure

R.M. Wolf: Research Support; Dexcom, Inc., Boehringer-Ingelheim, Novo Nordisk. D. Alver: None. B. Pan: None. N. Parimi: None. M.S. Klopouh: None. T.D. Liu: None. A.D. Liu: None. A. Sidhaye: None. K. Riekert: Consultant; Vertex Pharmaceuticals Incorporated. N.N. Mathioudakis: None.

Funding

NIDDK (1R01DK134955-01)
DESAFIOS NA GESTÃO PATRIMONIAL: INVESTIGAÇÃO EM UMA INSTI-TUIÇÃO FEDERAL DE ENSINO
Authors: Sá Rosimere Gomes de , Barbosa Marcos Antonio de Souza
Published: June 2024

Este estudo examinou a gestão de bens móveis permanentes em uma instituição federal de ensino, sob o modelo integrado COSO ERM, analisando como práticas e procedimentos influenciam o aumento de bens móveis permanentes não localizados. Foi avaliada a eficácia dos processos de gestão de risco e controle, bem como a implementação de estratégias de informação e comunicação após a entrada e saída de bens na instituição. A pesquisa adotou uma abordagem qualitativa, usando análise documental e entrevistas em um estudo de caso único. Os resultados, foram analisados utilizando a análise de conteúdo e indicaram a necessidade de aprimorar a gestão patrimonial, especialmente em termos de comunicação interna, conformidade com diretrizes estabelecidas e treinamento dos coordenadores de patrimônio. Recomenda-se ampliar o número de entrevistados em futuras pesquisas para obter uma compreensão mais abrangente das práticas e desafios enfrentados na gestão de bens móveis permanentes em instituições de ensino.
Palavras-chave: Gestao patrimonial, Governança, Gestao de risco e Controle interno.
El rol docente entre el ethos y las virtudes del profesorado. Reflexiones y saberes
Authors: Ruiz de la Torre Gabriela , Barbosa Muñoz Perla Araceli , Sáenz Gallegos María Luisa
Published: June 2024

El propósito de este artículo es presentar una variedad de recomendaciones y conocimientos docentes, junto con estrategias de trabajo, que buscan mejorar la dinámica escolar a través de la reflexión sobre el ethos y la ética docente con el objetivo de promover una práctica docente pertinente y adaptada a las necesidades educativas actuales. Para ello, la metodología se fundamentó en un estudio cuantitativo, no experimental, transversal y descriptivo, utilizando una muestra conveniente de 60 docentes de Morelia, Michoacán (México), que abarcó los niveles básico, medio superior y superior. En concreto, se administró una encuesta estructurada basada en los elementos encontrados en la literatura actual sobre el ethos docente, y se empleó estadística descriptiva para analizar los datos, utilizando Excel y el paquete estadístico SPSS, versión 25. El estudio reveló que la población encuestada reconoce ampliamente la importancia del ethos y la ética en su práctica docente, así como el papel crucial de la enseñanza en valores, la empatía, la mediación y la escucha activa en la formación integral de los estudiantes.
Pembuatan Sabun Facial Wash Berbasis Minyak Kelapa Murni (Virgin Coconut Oil) dengan Penambahan Ekstrak Kulit Pisang Ambon (Musa Parisidiaca L.) Sebagai Anti Hiperpigmentasi
Authors: Dini Hanny Sekar , Fuadi Ahmad M.
Published: June 2024

Sabun facial wash adalah salah satu jenis sabun yang memiliki fungsi membersihkan wajah dari kotoran dan  memiliki kandungan yang mampu menjaga kelembaban dan menenangkan kulit wajah. Bahan baku utama pembuatan sabun adalah minyak dan lemak, salah satu bahan campuran pembuatan sabun facial wash adalah minyak kelapa murni (virgin coconut oil) diyakini memiliki banyak manfaat pada komposisinya yang terdiri dari asam lemak jenuh rantai sedang dan bersifat anti mikroba. Kulit buah pisang mengandung senyawa flavonoid sebagai anti hyperpigmentasi. Hyperpigmentasi merupakan salah satu kondisi munculnya bercak gelap pada kulit yang diakibatkan paparan sinar matahari, penuaan, hemokromatosis dan penggunaan obat-obatan tertentu. Tujuan penelitian ini adalah untuk mengetahui hasil pembuatan sabun facial wash berbasis minyak kelapa murni (virgin coconut oil) dengan penambahan ekstrak kulit pisang ambon dengan uji organoleptic dan skala hedonic. Penelitian ini dilakukan terhadap sepuluh panelis dengan penilaian banyak busa, warna, aroma, tekstur, dan reaksi alergi. Panelis diminta memberikan penilaian dengan produk sabun facial wash yang ada dipasaran (produk pembanding).  Berdasarkan hasil uji organoleptic didapatkan hasil penilaian produk facial wash berbasis minyak kelapa murni dengan ekstrak kulit pisang ambon (Musa Paradisiaca L.) sebagai anti hiperpigmentasi mendapatkan point lebih unggul pada uji organoleptic warna dan aroma. Sedangkan, pada produk pembanding mendapatkan point lebih unggul pada uji organoleptic banyak busa dan tekstur. Namun, tidak terjadi reaksi alergi pada sepuluh panelis terhadap kedua produk.
Comparison the Effectiveness of Silica Sand and Resin Filter Media on Reducing Phosphate Levels of Wastewater of PKU Muhammadiyah Hospital Surakarta
Authors: Asharani Regita , Sugiharto Agung , Khuzaimah Siti , Estiyantara Nurhadi
Published: June 2024

Liquid waste containing phosphates has an effect on human health. Phosphate levels based on the results of preliminary tests carried out at the PKU Muhammadiyah Hospital in Surakarta were 5.7 mg/L; these results exceeded wastewater quality standards. There are many ways to reduce phosphate levels to comply with wastewater quality standards, including adding PAC coagulants, alum, and others. However, this is less effective when applied to hospital wastewater, so the researchers used the filtration method to reduce phosphate levels. The filtration method is a filtering process that separates particles or sediment so that they are not carried away with the treated water ready for discharge. The filter media used include zeolite, activated carbon, resin, silica sand, and many more. In this research, only two filter media were used, comparing the effectiveness of silica sand and resin filter media. Processing used variations in column height of 60 cm, 80 cm, and 100 cm, employing slow filter filtration experimental methods and laboratory tests to reduce phosphate levels in wastewater from PKU Muhammadiyah Hospital Surakarta.
Activated Periodates and Sodium Percarbonate in Advanced Oxidation Processes of Organic Pollutants in Aqueous Media: A Review
Authors:   Lviv Polytechnic National University 12, S. Bandery St., Lviv 79013, Ukraine, Sukhatskiy Yuriy , Znak Zenovii ,   Lviv Polytechnic National University 12, S. Bandery St., Lviv 79013, Ukraine, Sozanskyi Martyn ,   Lviv Polytechnic National University 12, S. Bandery St., Lviv 79013, Ukraine, Shepida Mariana ,   Lviv Polytechnic National University 12, S. Bandery St., Lviv 79013, Ukraine, Gogate Parag R. ,   Institute of Chemical Technology, Matunga, Mumbai 40019, India, Tsymbaliuk Volodymyr ,   Lviv Polytechnic National University 12, S. Bandery St., Lviv 79013, Ukraine
Published: June 2024

The methods of periodates and sodium percarbonate activation are considered for planning strategic approaches to increasing the efficiency and intensity of oxidative degradation of organic pollutants in aquatic environments. A classification of periodate activation methods is proposed, including activation methods by external energy effects, catalytic activation methods, and other activation methods (e.g., by hydrogen peroxide, by hydroxylamine, activation in alkaline medium). Activation methods for sodium percarbonate were divided into homogeneous and heterogeneous activation methods.
Hydrogels in Biomedicine: Granular Controlled Release Systems Based on 2-Hydroxyethyl Methacrylate Copolymers. A Review
Authors:   Lviv Polytechnic National University, 12 Bandery St., 79013 Lviv, Ukraine, Semenyuk Nataliya , Dudok Galyna ,   Lviv Polytechnic National University, 12 Bandery St., 79013 Lviv, Ukraine, Skorokhoda Volodymyr ,   Lviv Polytechnic National University, 12 Bandery St., 79013 Lviv, Ukraine
Published: June 2024

The article analyzes and summarizes the latest achievements in the field of polymer systems for controlled release devices based on hydrogel materials. Possible directions of drug delivery are presented, including the use of granular hydrogels, which work on the principle of drug sorption − release in the body. The research on the synthesis regularities, structure, properties, and prospects for the use of granular hydrogels based on 2-hydroxyethyl methacrylate (HEMA) and its copolymers, in particular with polyvinylpyrrolidone (PVP), as systems for the controlled release of substances, in particular, drugs, is analyzed.
Matching of the Project Manager’s Approach and the Project Delivery System to Achieve Project Success in Yemeni Projects
Authors: Nasser Fahd Mahmood Mohammed , Alawi Nahg Abdulmajid , Mustaffa Abaidullah , Yusuf Asniza , Al-Refaei Abd Al-Aziz , Mahmood Mohammed Mahmood Fahd
Published: June 2024

The goal of this study is to seek answers to whether project managers’ approach is influenced by the project delivery system for achieving project success in Yemeni projects. A quantitative approach was adopted in this paper, and 375 project managers from two governorates of Yemen served as respondents. The idea is to assess the connection between the project managers’ approach (PMA) and the project delivery system (PDS). The results revealed that the project manager’s approach (participative and directive) and alignment with the project delivery systems (traditional or design and build) were directly linked with project success or failure. Moreover, the results revealed that the project managers adopting a participative approach have constructive effects, while the project managers adopting a directive approach harm project success. It is a chance for inexperienced project managers to receive advice on how to implement their management strategy and learn that, for Yemeni projects (YPs), every project delivery system requires a suitable approach to leadership.
Entsorgungsverkehre auf dem Wasser
Authors: Decker Thomas
Published: June 2024

Das Forschungsprojekt „GüllOst“ der Rheinischen Fachhochschule Köln (Standort Neuss) zielt ab auf ein Logistik-Konzept, das die durch sogenannte „Nährstoffbörsen“ oder „Güllebanken“ verursachten Quell-, Ziel- und Transitverkehre für organischen Dünger zu optimieren sucht. Ziel ist dabei insbesondere, entsprechende LKW-Verkehre auf Binnenschiffe zu verlagern und dabei den Mittellandkanal als den Weg des Hauptlaufs in den Fokus zu rücken.
Die letzte Meile neu gedacht
Authors: Schulte Patrick
Published: June 2024

Im Zuge der digitalen Transformation sieht sich auch der Einzelhandel mit der Herausforderung der Last Mile Logistik konfrontiert. Dass sich sogar Same Day Delivery mit einer sehr persönlichen Note umsetzen lässt, demonstriert das regionale Internetkaufhaus Lokaso.
Güter auf die Bahn?
Authors: Engelhardt Dirk
Published: June 2024

Die verkehrspolitische Diskussion im Warentransport kreist seit Jahrzehnten um den Slogan „Güter gehören auf die Bahn“. Aber warum eigentlich? Betrachtungen über den Wettbewerb der Verkehrsträger im Warentransport von Prof. Dr. Dirk Engelhardt, Hauptgeschäftsführer des Bundesverbandes Güterkraftverkehr Logistik und Entsorgung (BGL) e.V., Frankfurt am Main.
Akzeptanz für automatisiertes Fahren
Authors: Dütschke Elisabeth , Schneider Uta , Krail Michael , Peters Anja
Published: June 2024

Automatisiertes Fahren wird als Baustein einer nachhaltigen Verkehrswende diskutiert. Erste Studien zur gesellschaftlichen Akzeptanz liegen nun vor. Der Beitrag geht auf Basis einer Literatur-Aufarbeitung der Frage nach, wie ein gesellschaftlich akzeptierter Weg zu einem automatisierten Verkehrssystem aussehen könnte. Insgesamt zeichnet sich ab, dass sowohl bei Bürgerinnen und Bürgern als auch in der Forschung die Vorstellung eines automatisierten motorisierten Individualverkehrs dominiert, was zu einem höheren Verkehrsaufkommen führen könnte.
Kommunales Engagement im Ausbau von Carsharing für den ländlichen Raum
Authors: Seemann Ann-Kathrin , Knöchel Sebastian
Published: June 2024

Die qualitative Studie setzt sich mit dem Mobilitätskonzept Carsharing im ländlichen Raum auseinander und beschreibt den gegenwärtigen Stand der Forschung, gefolgt von dem methodischen Ansatz sowie den Ergebnissen der Analyse, die mit einem Logikmodell visualisiert werden. Die Ergebnisse zeigen auf, dass Carsharing über Wachstumspotenzial in ländlichen Gebieten verfügt. Dabei spielen insbesondere die kommunale Unterstützung, Bürgerengagement sowie die Integration potentieller Stakeholder eine Schlüsselrolle bei der Steigerung des Potenzials dieser Mobilitätsform in ländlichen Gebieten.
Mobilitätsmonitor Nr. 5 - November 2017
Authors: Scherf Christian , Hunsicker Frank , Bock Benno , Damrau Lena , Epp Julia , Hilwerling Benno , Schelewsky Marc , Schmidt Anke
Published: June 2024

Das InnoZ und seine Partner erstellen ein Monitoring aus Basisdaten zum Personenverkehrsmarkt in Deutschland. Vergleiche mit weiteren Daten veranschaulichen den Stand der Verkehrswende, d. h. die Entstehung eines nachhaltigen, vernetzten und automatisierten Mobilitätssystems. Die Besonderheit dabei ist die vergleichende Betrachtung von Gesamt- und Nischenmärkten mittels externer Datenquellen sowie eigener Erhebungsformen.
Einflussfaktoren auf Check-in-Wartezeiten am Beispiel des Flughafens Hamburg
Authors: Bießlich Peter , Schwetge Björn , Lütjens Klaus , Gollnick Volker
Published: June 2024

Passagiere empfinden Wartezeiten während ihrer Reise als verlorene Zeit. Auf Flugreisen treten Wartezeiten jedoch häufig an verschiedenen Prozessstellen innerhalb eines Flughafens auf und können Unzufriedenheit oder sogar Stress auslösen. Am Beispiel des Flughafens Hamburg werden Einflussfaktoren analysiert, die speziell beim Check-in zu zeitlichen Prozessverzögerungen führen. Auf Basis der Ergebnisse einer Beobachtungsstudie werden Empfehlungen aufgezeigt, wie einerseits Wartezeiten und anderseits Konfusion und Stress unter den Passagieren am Check-in vermieden werden können.
Ausgezeichnete Hindernisse
Authors: Sauter Michael
Published: June 2024

Die Datenbank Lido/SurfaceData liefert weltweite Hindernisdaten an Softwareentwickler und Avionikhersteller, und sie gewann den Deutschen Mobilitätspreis 2017. Die Lösung kennt mehr als eine Million Hindernisse auf der ganzen Welt. Davon profitieren Airlines, Flughafenbetreiber, Drohnenproduzenten und Avionikhersteller.
The British way of long distance transport
Authors: Schneider Philipp
Published: June 2024

Similarities and fundamental differences – both diagnoses are appropriate comparing the British and German long distance land transport sectors. Whereas the British rail franchising system is unique in Europe, the coach sectors have converged in a remarkably short period since the deregulation in Germany in 2013. Learning from the British case is instructive – particularly in the light of a proposed Long Distance Passenger Rail Act.
Der Löwe setzt auf Wachstum
Authors: Ruppik Dirk
Published: June 2024

Der Stadtstaat Singapur macht sich auf, anstehende Herausforderungen in der Zukunft schon jetzt zu lösen. Im Logistikbereich gehören dazu auch Umsiedelung und Zusammenlegung fast aller Terminals ins südwestliche Tuas sowie der weitere Ausbau von Changi. Wie Hongkong will auch Singapur hochwertiges verabeitendes Gewerbe sowie Forschung und Entwicklung in den Stadtstaat ziehen.
Urbane Mobilität - auf dem Weg zu Mobility on Demand
Authors: Frisch Ralf
Published: June 2024

Themen wie Verkehrsstaus und gesundheitsschädliche Emissionen beschäftigen die Gesellschaft vor allem in urbanen Räumen seit vielen Jahren – weitgehend erfolglos. Wie kann „Mobility as a Service“ die Lösung bringen? Ein Beitrag von Ralf Frisch, Solution Director MaaS – Mobility as a Service bei der PTV Group, Karlsruhe.
Ein Meilenstein für die autonome Schifffahrt
Authors: Daffey Kevin
Published: June 2024

Die norwegischen Gemeinden Anda und Lote werden bald die ersten Ortschaften sein, die in den Genuss sicherer und effizienter Überfahrten kommen, bei denen die Fähre von selbst fährt. Die Einführung von Rolls-Royce Autocrossing bringt uns einer Welt, in der Schiffe autonom fahren, einen weiteren Schritt näher. Es vereinfacht den Fährbetrieb und minimiert den Energieverbrauch pro Fahrt.